Pliant Therapeutics GAAP EPS of -$0.39 misses by $0.02
Pliant Therapeutics reported Q3 GAAP EPS of -$0.39, missing estimates by $0.02. The company had $142.6M in cash and short-term investments as of September 30, 2026, expecting it to last until mid-2028, according to the company.
How this was made
The 30-second read
Why it matters
The earnings miss may prompt short sellers, but the ample cash position provides runway, potentially limiting severe price declines.
Market read
Primary earnings news for a micro‑cap biotech; relevant for short‑term traders monitoring earnings surprises.
What to watch
The company still has $142.6 million cash, sufficient to fund operations through mid‑2028, which could cushion the downside.
Background
Pliant Therapeutics (PLRX) reported its Q3 2026 GAAP earnings, showing a slight EPS miss.
Ticker impact
Q3 GAAP EPS of -$0.39 missed consensus by $0.02, disclosed in the company's press release.
likely downside as market prices in the earnings miss
The miss is a fresh primary disclosure; investors typically react negatively to EPS shortfalls.
Market effects
Minimal impact on the broader biotech sector; the miss is company‑specific.
Limited to U.S. small‑cap biotech investors.
Low; no macro or global implications.
Counterpoint
If the miss is within expectations, the stock may rebound on the cash runway to mid‑2028.
Key entities
- CompanyPliant Therapeutics, Inc.
Biotech firm listed on Nasdaq under ticker PLRX.
